Warburg hypothesis
The Warburg hypothesis (/ˈvɑːrbʊərɡ/), sometimes known as the Warburg theory of cancer, postulates that the driver of tumorigenesis is an insufficient cellular respiration caused by insult to mitochondria.[1] The term Warburg effect in oncology describes the observation that cancer cells, and many cells grown in vitro, exhibit glucose fermentation even when enough oxygen is present to properly respire.[2] In other words, instead of fully respiring in the presence of adequate oxygen, cancer cells ferment. The Warburg hypothesis was that the Warburg effect was the root cause of cancer. The current popular opinion is that cancer cells ferment glucose while keeping up the same level of respiration that was present before the process of carcinogenesis, and thus the Warburg effect would be defined as the observation that cancer cells exhibit glycolysis with lactate production and mitochondrial respiration even in the presence of oxygen.[3][4]
Hypothesis
The hypothesis was postulated by the Nobel laureate Otto Heinrich Warburg in 1924.[5] He hypothesized that cancer, malignant growth, and tumor growth are caused by the fact that tumor cells mainly generate energy (as e.g., adenosine triphosphate / ATP) by non-oxidative breakdown of glucose (a process called glycolysis). This is in contrast to healthy cells which mainly generate energy from oxidative breakdown of pyruvate. Pyruvate is an end-product of glycolysis, and is oxidized within the mitochondria. Hence, according to Warburg, carcinogenesis stems from the lowering of mitochondrial respiration. Warburg regarded the fundamental difference between normal and cancerous cells to be the ratio of glycolysis to respiration; this observation is also known as the Warburg effect.
Cancer is caused by mutations and altered gene expression, in a process called malignant transformation, resulting in an uncontrolled growth of cells.[6][7] The metabolic difference observed by Warburg adapts cancer cells to the hypoxic (oxygen-deficient) conditions inside solid tumors, and results largely from the same mutations in oncogenes and tumor suppressor genes that cause the other abnormal characteristics of cancer cells.[8] Therefore, the metabolic change observed by Warburg is not so much the cause of cancer, as he claimed, but rather, it is one of the characteristic effects of cancer-causing mutations.
Warburg articulated his hypothesis in a paper entitled The Prime Cause and Prevention of Cancer which he presented in lecture at the meeting of the Nobel-Laureates on June 30, 1966 at Lindau, Lake Constance, Germany. In this speech, Warburg presented additional evidence supporting his theory that the elevated anaerobiosis seen in cancer cells was a consequence of damaged or insufficient respiration. Put in his own words, "the prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar."[9]
The body often kills damaged cells by apoptosis, a mechanism of self-destruction that involves mitochondria, but this mechanism fails in cancer cells where the mitochondria are shut down. The reactivation of mitochondria in cancer cells restarts their apoptosis program.[10]
Continuing research and interest
A large number of researchers have dedicated and are dedicating their efforts to the study of the Warburg effect that is intimately associated with the Warburg hypothesis. In oncology, the Warburg effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol,[11][12] rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.[13][14][15] Interestingly, researchers found that under obesity, tumor cells invert the metabolic flow by producing glucose by gluconeogenesis using lactic acid and other metabolic sources as substrates. This process in known as Warburg effect inversion.[16]
In particular, almost 18,000 publications have been published on the matter of ATP and the Warburg effect in the period 2000 to 2015. Most of the functions of the Warburg Effect have been the object of study.[17] Thousands of publications claim to have determined its functions or causes.
Warburg effect in Tuberculosis
Tuberculosis is caused by Mycobacterium tuberculosis. Recently it has been shown that chronic infection of M. tuberculosis instigates expression upregulation of glycolysis pathway genes in peripheral blood mononuclear cells (PBMCs). Ex-vivo infection of non-pathogenic mycobacteria (M.bovis) in PBMCs and THP-1 macrophage increase glucose uptake, glucose consumption and lactate production. Increased glucose uptake and increased glucose consumption is also known as glucose fermentation. This phenomenon is mediated through NIX receptor-mediated mitophagy pathway [18]
See also
References
- Warburg O (24 February 1956). "On the Origin of Cancer Cells". Science. 123 (3191): 309–14. Bibcode:1956Sci...123..309W. doi:10.1126/science.123.3191.309. PMID 13298683.
- Mahla, RS; et al. (2021). "NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection". Tuberculosis. 126 (January): 102046. doi:10.1016/j.tube.2020.102046.
- Alfarouk, KO; Verduzco, D; Rauch, C; Muddathir, AK; Adil, HH; Elhassan, GO; Ibrahim, ME; David Polo Orozco, J; Cardone, RA; Reshkin, SJ; Harguindey, S (2014). "Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question". Oncoscience. 1 (12): 777–802. doi:10.18632/oncoscience.109. PMC 4303887. PMID 25621294.
- Vazquez, A.; Liu, J.; Zhou, Y.; Oltvai, Z. (2010). "Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited". BMC Systems Biology. 4: 58. doi:10.1186/1752-0509-4-58. PMC 2880972. PMID 20459610.
- O. Warburg, K. Posener, E. Negelein: Ueber den Stoffwechsel der Tumoren; Biochemische Zeitschrift, Vol. 152, pp. 319-344, 1924. (in German). Reprinted in English in the book On metabolism of tumors by O. Warburg, Publisher: Constable, London, 1930.
- Bertram JS (2000). "The molecular biology of cancer". Mol. Aspects Med. 21 (6): 167–223. doi:10.1016/S0098-2997(00)00007-8. PMID 11173079.
- Grandér D (1998). "How do mutated oncogenes and tumor suppressor genes cause cancer?". Med. Oncol. 15 (1): 20–6. doi:10.1007/BF02787340. PMID 9643526. S2CID 12467031.
- Hsu PP, Sabatini DM (2008). "Cancer Cell Metabolism: Warburg and Beyond". Cell. 134 (5): 703–7. doi:10.1016/j.cell.2008.08.021. PMID 18775299. S2CID 17778749.
- Brand, R. A. (2010). "Biographical Sketch: Otto Heinrich Warburg, PhD, MD". Clinical Orthopaedics and Related Research. 468 (11): 2831–2832. doi:10.1007/s11999-010-1533-z. PMC 2947689. PMID 20737302.
- Pedersen, Peter L (February 2007). "The cancer cell's "power plants" as promising therapeutic targets: an overview". Journal of Bioenergetics and Biomembranes. 39 (1): 1–12. doi:10.1007/s10863-007-9070-5. ISSN 0145-479X. PMID 17404823. S2CID 477272.
- Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, Ibrahim ME, David Polo Orozco J, Cardone RA, Reshkin SJ, Harguindey S (2014). "Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question". Oncoscience. 1 (12): 777–802. doi:10.18632/oncoscience.109. PMC 4303887. PMID 25621294.
- Alfarouk KO (February 2016). "Tumor metabolism, cancer cell transporters, and microenvironmental resistance". Journal of Enzyme Inhibition and Medicinal Chemistry. 31 (6): 859–866. doi:10.3109/14756366.2016.1140753. PMID 26864256.
- Alfarouk KO, Muddathir AK, Shayoub ME (20 January 2011). "Tumor acidity as evolutionary spite". Cancers. 3 (1): 408–14. doi:10.3390/cancers3010408. PMC 3756368. PMID 24310355.
- Gatenby RA, Gillies RJ (November 2004). "Why do cancers have high aerobic glycolysis?". Nature Reviews. Cancer. 4 (11): 891–9. doi:10.1038/nrc1478. PMID 15516961. S2CID 10866959.
- Kim JW, Dang CV (September 2006). "Cancer's molecular sweet tooth and the Warburg effect". Cancer Research. 66 (18): 8927–30. doi:10.1158/0008-5472.CAN-06-1501. PMID 16982728.
- Luis, C; Duarte, F; Faria, I; Jarak, I; Oliveira, PF; Alves, MG; Soares, R; Fernandes, R (2019). "Warburg Effect Inversion: Adiposity shifts central primary metabolism in MCF-7 breast cancer cells". Life Sciences. 223: 38–46. doi:10.1016/j.lfs.2019.03.016. PMID 30862570. S2CID 76665891.
- The Warburg Effect: How Does it Benefit Cancer Cells? Trends in Biochemical Sciences- M.V. Liberti, J.W. Locasale. January 2016
- Mahla, RS; et al. (2021). "NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection". Tuberculosis. 126 (January): 102046. doi:10.1016/j.tube.2020.102046. PMID 33421909.
Further reading
- Warburg O (24 February 1956). "On the Origin of Cancer Cells". Science. 123 (3191): 309–14. Bibcode:1956Sci...123..309W. doi:10.1126/science.123.3191.309. PMID 13298683.
- Ristow M (July 2006). "Oxidative metabolism in cancer growth". Current Opinion in Clinical Nutrition and Metabolic Care. 9 (4): 339–45. doi:10.1097/01.mco.0000232892.43921.98. PMID 16778561. S2CID 27603356.
- ""Energy Blocker" kills Big Tumors in Rats" (Press release). Johns Hopkins Medicine. 14 October 2004.
- Gatenby RA, Gillies RJ (2004). "Why do cancers have high aerobic glycolysis?" (reprint). Nature Reviews Cancer. 4 (11): 891–9. doi:10.1038/nrc1478. PMID 15516961. S2CID 10866959.
- Pelicano H, Martin DS, Xu RH, Huang P (2006). "Glycolysis inhibition for anticancer treatment". Oncogene. 25 (34): 4633–46. doi:10.1038/sj.onc.1209597. PMID 16892078.
- Weinhouse S (1976). "The Warburg hypothesis fifty years later". Journal of Cancer Research and Clinical Oncology. 87 (2): 115–26. doi:10.1007/BF00284370. PMID 136820. S2CID 1856214.
- Garber K (2004). "Energy Boost: The Warburg Effect Returns in a New Theory of Cancer". Journal of the National Cancer Institute. 96 (24): 1805–6. doi:10.1093/jnci/96.24.1805. PMID 15601632.
- Seyfried TN, Mukherjee P (Oct 2005). "Targeting energy metabolism in brain cancer: review and hypothesis". Nutr Metab (Lond). 2 (1): 30. doi:10.1186/1743-7075-2-30. PMC 1276814. PMID 16242042.
- Pedersen PL (Jun 2007). "Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen". J Bioenerg Biomembr. 39 (3): 211–22. doi:10.1007/s10863-007-9094-x. PMID 17879147. S2CID 43490722.
- Glycolytic enzyme inhibitors as novel anti-cancer drugs (3-bromopyruvate (3BP) and iodoacetate (IAA)), James C.K. Lai et al., Idaho State, June 2007
- Can a High-Fat Diet Beat Cancer? by Richard Friebe, Time magazine, Monday, Sep. 17, 2007,
- Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E (Mar 2007). "Energy metabolism in tumor cells". FEBS J. 274 (6): 1393–418. doi:10.1111/j.1742-4658.2007.05686.x. PMID 17302740.
- Pedersen PL (Feb 2007). "The cancer cell's "power plants" as promising therapeutic targets: an overview". J Bioenerg Biomembr. 39 (1): 1–12. doi:10.1007/s10863-007-9070-5. PMID 17404823. S2CID 477272.
- Aft RL, Zhang FW, Gius D (Sep 2002). "Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death". Br J Cancer. 87 (7): 805–12. doi:10.1038/sj.bjc.6600547. PMC 2364258. PMID 12232767.
- US 6670330 Cancer chemotherapy with 2-deoxy-D-glucose
- Can Ancient Herbs Treat Cancer? Time magazine, October 15, 2007 (describes the drug trial of BZL101, a compound from the Scutellaria Barbata herb that prevents cancerous cells from undergoing glycolysis).
- Isidoro A, Casado E, Redondo A, et al. (Dec 2005). "Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis". Carcinogenesis. 26 (12): 2095–104. doi:10.1093/carcin/bgi188. PMID 16033770.